Contents in the Video:

00:00

Keynote-426: consistent benefit shown for the update, especially for patients with IMDC intermediate or poor risk and in pts whose tumors had sarcomatoid features

01:52

Carmena confirms last year's findings that CN is not superior to sunitinib alone in ITT population, but might be beneficial for patients with only one IMDC risk factor

02:47

Alliance: Addition of bevacizumab shows no benefit for patients with metastatic urothelial carcinoma

03:36

Pembrolizumab as maintenance therapy may improve responses achieved with first line chemotherapy in patients with metastatic urothelial cancer

05:45

Late breaking abstract shows most promising results for enfortumab vedotin monotherapy in pretreated patients

Interview with:

Priv.-Doz. Dr. Richard Cathomas

Interview by:

Dr. Rosalia Rutter

Produced by:

Mag. Oliver Eberhardt

Dr. Rosalia Rutter

Dr. Rosalia Rutter

4 Jun 2019

ASCO 2019: Breakfast Brief – Genitourinary cancers

PD Dr. Richard Cathomas, Kantonsspital Chur, Graubünden, talks about the most interesting studies in genitourinary cancers presented at this year’s ASCO.